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Abstract
Introduction: Systemic sclerosis (SSc) is more prevalent in women. Our goal is to determine the effects of 17b-
estradiol (E2) on the development of fibrosis and to compare circulating levels of estrogens in SSc patients and
healthy controls.
Methods: Using primary human dermal fibroblasts, we evaluated the effect of E2 on fibronectin (FN) expression
with and without the estrogen receptor (ER) antagonist ICI 182,780, inhibitors of signaling, propyl-pyrazole-triol, an
ERa specific ligand, and genistein, an ERb selective ligand, to identify the signaling pathways mediating E2’s effect.
We confirmed the fibrotic effect of E2 in human skin using an ex vivo organ culture model. Lastly, we measured
levels of E2 and estrone in serum samples from SSc patients with diffuse cutaneous involvement and healthy
controls using mass spectrometry.
Results: E2 increased expression of FN in dermal fibroblasts. ICI 182,780, inositol-1,4,5-triphosphate inhibitor, and
p38 mitogen-activated protein kinase inhibitor blocked the effects of E2 on FN. Propyl-pyrazole-triol, but not
genistein, significantly increased FN expression. Ex vivo, E2 induced fibrosis of human skin. The effects of E2 were
abrogated by ICI 182,780. Circulating levels of E2 and estrone were significantly increased in sera of patients with
diffuse cutaneous SSc.
Conclusion: Our findings implicate estrogens in the fibrotic process and may explain the preponderance of SSc in
women. ICI 182,780 or other ER signaling antagonists may be effective agents for the treatment of fibrosis.
Introduction
Systemic sclerosis (SSc) is a connective tissue disease
characterized by fibrosis of the skin and internal organs
due to fibroblast proliferation and excessive production
of extracellular matrix (ECM) [1]. The mechanism(s)
resulting in fibrosis in SSc are still under investigation.
There are currently no effective treatments to prevent
or halt the progression of fibrosis in SSc or other fibros-
ing diseases [2]. SSc has a worldwide distribution and is
more frequent in women than men [3]. The female:male
ratio is approximately 3:1, but this ratio increases to
10:1 during the child-bearing years [1]. Female sex
hormones such as estrogens may thus contribute to dis-
ease pathogenesis.
There are three main estrogens: estradiol, estrone, and
estriol. Estradiol and estrone are the estrogens found in
nonpregnant women, while estriol is the estrogen of
pregnancy. Estrogens, especially 17b-estradiol (E2), play
an important role in many normal physiological pro-
cesses in mammals such as reproduction, cardiovascular
health, bone integrity, cognition, and behavior [3]. Given
this widespread role for E2 in human physiology, E2 is
also implicated in the development or progression of
numerous diseases - including various types of cancer
(breast, ovarian, colorectal, prostatic, endometrial), osteo-
porosis, neurodegenerative diseases, cardiovascular dis-
ease, insulin resistance, endometriosis, and obesity [4-8].
In many of these disorders, estrogen mediates its effects
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through the estrogen receptors (ERs), which serve as the
targets for many therapeutic interventions.
The clinical effects of hormone replacement therapy
(HRT) and tamoxifen, a selective ER modulator, have
been evaluated in SSc patients [9,10]. HRT was sug-
gested to exert protective effects against the develop-
ment of isolated pulmonary hypertension in patients
with SSc and limited cutaneous involvement [9], while
tamoxifen did not improve SSc symptoms [10]. We
examined the effects of E2 on fibronectin (FN), an
important component of the ECM, and on the develop-
ment of dermal fibrosis in human skin in organ culture.
We also compared estrogen levels in sera of patients
with diffuse cutaneous SSc and healthy controls.
Materials and methods
Source of fibroblasts
Skin-punch biopsies were obtained with informed consent
under an Institutional Review Board-approved protocol at
the University of Pittsburgh from the clinically affected
and unaffected skin of six patients with SSc and five
healthy twins from an existing twin cohort [11,12].
Healthy twins were used as controls since they share the
genetic background as the SSc patients. All SSc patients
had diffuse skin thickening and met the American College
of Rheumatology preliminary criteria for classification as
SSc [1].
Biopsies were performed on the leading edge of dermal
thickening and clinically normal skin. The skin samples
were minced, placed in 60 mm tissue culture dishes, and
cultured at 37°C in a humidified atmosphere in DMEM
(Cellgro, Herndon, VA, USA) supplemented with 10% fetal
bovine serum (Sigma-Aldrich, St Louis, MO, USA), 100
IU/ml penicillin, and 100 μg/ml streptomycin (Invitrogen,
Carlsbad, CA, USA).
Serum samples
Serum was obtained from postmenopausal patients with
diffuse cutaneous SSc (n = 68) and from age-matched and
sex-matched healthy controls (n = 35). Both groups had
no exposure to HRT. The average age of the SSc patients
was 67.6 ± 5.2 years and that of controls 66 ± 0.84 years
(not significant). Patients with SSc had disease duration <3
years, with onset defined as the time of the first symptom
attributable to SSc.
Treatment of cells with 17b-estradiol, ER ligands and 17b-
estradiol signaling inhibitors
Skin fibroblasts (2×105 cells per well) were seeded in 35
mm cell culture dishes in DMEM/10% fetal bovine
serum. The following day, the medium was replaced
with phenol-red free DMEM (Cellgro) without serum
for 24 hours to deprive the cells of estrogen. Fresh phe-
nol red-free DMEM plus 10% charcoal-stripped fetal
bovine serum (Hyclone, Logan, UT, USA) was added with
one of the following: ethanol as vehicle control (0.1%) or
E2 (10 nM; Sigma-Aldrich) for 24 hours (for RNA extrac-
tion) or 48 hours (for protein extraction). Transforming
growth factor beta (10 ng/ml; R&D Systems, Minneapolis,
MN, USA) was used as a positive control. ICI 182,780
(100 nM; Tocris, Ballwin, MO, USA), a pure ER antago-
nist, and signaling inhibitors (MEK inhibitor U0126, inosi-
tol-1,4,5-triphosphate (PI3K) inhibitor LY294002, and p38
mitogen-activated protein kinase (MAPK) inhibitor
SB202190, 10 μM each; Cell Signaling Technology,
Beverly, MA, USA) were added where indicated. To deter-
mine the role of ERa and ERb on FN individually, cells
were cultured with propyl-pyrazole-triol (PPT), an ERa
specific ligand (100 nM; Tocris) [13], and genistein, an
ERb selective ligand (100 nM; Sigma-Aldrich), under
similar conditions to those used for E2 treatment.
Extracellular matrix extraction
ECM was extracted as we have described previously
[14]. Briefly, cells were rinsed with PBS and incubated
with 8 M urea in PBS for 20 minutes. Cells were aspi-
rated and the ECM was rinsed three times with PBS.
ECM from an equal number of cells was scraped in 100
μl sample buffer (20 mM dithiothreitol, 6% SDS, 0.25 M
Tris, pH 6.8, 10% glycerol, 10 mM NaF, and bromophe-
nyl blue) and analyzed by western blot. Equal volumes
of ECM were loaded in each lane.
RNA isolation and RT-PCR
Skin fibroblasts in early passage (passages 3 and 4) were
harvested and RNA was extracted using TRIzol (Invitro-
gen). mRNA was reverse transcribed using Superscript II
(Invitrogen) following the manufacturer’s recommenda-
tions. The cDNA generated was used as a template for
amplification by PCR with primers specific for FN, 5’-
ACCGTGTGGGTACAGGTG-3’ and 5’-GTCACAGAGG
CTACTAT-3’, and b-actin, 5’-ATGTTTGAGACCTTCA
ACAC-3’ and 5’-CACGTCACACTTCATGATGG-3’. PCR
amplification was performed in a 50 μl reaction containing
Taq DNA polymerase (Invitrogen), 10× PCR buffer (750
mM Tris-HCl, pH 8.8, 200 mM (NH4)2SO4 and 0.1%
Tween 20), 1.5 mM MgSO4, and 1 mM of each deoxynu-
cleotide triphosphate in a Peltier Thermal Cycler-200 (MJ
Research, Waltham, MA, USA).
Conditions were an initial denaturation at 95°C for 4
minutes, followed by 35 cycles of 94°C for 45 seconds, 55°
C for 30 seconds, and 68°C for 2 minutes. Final extension
was at 68°C for 5 minutes. Then 20 μl each reaction was
electrophoresed on a 1% agarose gel in 1× Tris/acetate/
ethylenediamine tetraacetic acid buffer and products were
visualized following staining with ethidium bromide. The
molecular weights of the PCR products were: FN 513 bp
and b-actin 494 bp.
Aida-Yasuoka et al. Arthritis Research & Therapy 2013, 15:R10
http://arthritis-research.com/content/15/1/R10
Page 2 of 10
Protein extraction and western blot
Cells were grown to confluency in 35 mm culture dishes.
Cells were rinsed with 1× PBS and scraped in sample buf-
fer (20 mM dithiothreitol, 6% SDS, 0.25 M Tris, pH 6.8,
10% glycerol, 10 mM NaF, and bromophenyl blue). Sam-
ples were separated by electrophoresis on 8% SDS-polacry-
lamide gels and transferred to nitrocellulose membranes.
Membranes were blocked with 5% nonfat milk in 1× TBS-
Tween 20 (0.2 M Tris, 0.14 M NaCl, 0.1% Tween 20),
followed by incubation with mouse monoclonal anti-
human EDA-FN antibody, rabbit polyclonal anti-human
FN antibody, rabbit polyclonal anti-ERa antibody, rabbit
polyclonal anti-ERb antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), mouse monoclonal anti-human
vitronectin, mouse monoclonal anti-b-actin (Sigma-
Aldrich), or mouse monoclonal anti-GAPDH (Ambion,
Austin, TX, USA) in 1× TBS-Tween 20. Membranes were
then incubated with horseradish peroxide-conjugated don-
key anti-rabbit IgG (Amersham, Piscataway, NJ, USA) or
donkey anti-mouse IgG (Amersham). Immunoreactive
proteins were detected by chemiluminescence (PerkinEl-
mer Life Sciences, Boston, MA, USA), followed by
autoradiography.
Treatment of human skin ex vivo
Human abdominal skin was obtained from cosmetic
plastic surgery. All tissues were obtained according to
the guidelines of the University of Pittsburgh and under
a protocol approved by the Institutional Review Board
of the University of Pittsburgh. As described previously
[15], subcutaneous fat tissue was removed uniformly
and samples composed of complete epidermal and der-
mal strata were cut into 1.5 cm×1.5 cm sections. Skin
was maintained in organ culture in the presence of the
indicated factors, E2 (10 nM), ICI 182,780 (100 nM),
PPT (100 nM), and genistein (100 nM). Skin was har-
vested, fixed in 10% formalin, and embedded in paraffin.
Measurement of skin dermal and collagen bundle
thickness
Dermal and collagen bundle thickness were measured in
skin sections stained with H & E. Dermal thickness was
defined as the distance from the granular layer to the
junction between the dermis and subcutaneous fat.
Images were taken on a Nikon Eclipse 800 microscope
(Nikon Instruments, Inc., Huntley, IL, USA) using identi-
cal camera settings, and ImageJ (National Institutes of
Health, Bethesda, MD, USA) was used to measure thick-
ness. Thickness was measured in five random fields in
each sample.
Immunohistochemistry
Sections (6 μm) of paraffin-embedded skin tissues were
de-paraffinized, endogenous peroxidase was quenched
using 10% H2O2, and endogenous biotin was blocked
using the biotin blocking kit (Dakocytomation, Carpin-
teria, CA, USA). The sections were blocked with 5%
serum and incubated with anti-FN antibody followed by
secondary antibody. Bound secondary antibody was
detected using the aminoethyl carbazole Red kit (Invi-
trogen, Carlsbad, CA, USA). A light hematoxylin coun-
terstain was used to identify nuclei. Images were taken
on a Nikon Eclipse 800 microscope.
Measurement of 17b-estradiol and estrone in serum
Serum levels of E2 and estrone were measured using
liquid chromatography-tandem mass spectrometry in
the Small Biomolecule Core Facility in the School of
Pharmacy at the University of Pittsburgh. The liquid
chromatography-tandem mass spectrometry method
employs liquid-liquid extraction, derivatization, and
detection with a triple quad mass spectrometer using
0.5 ml serum.
Statistical analysis
For the in vitro and ex vivo data, statistical comparisons
were performed using the Mann-Whitney U test. For the
comparison of serum levels of E2 and estrone, two sepa-
rate sets of analyses were performed: case versus control
comparisons of estrone and E2; and case-only compari-
sons of clinical manifestations based on high, intermediate,
and low estrone or E2. For these comparisons, the Wil-
coxon rank-sum test, the chi-square test of proportions,
and Fisher’s exact test were used where appropriate.
Results
Effect of 17b-estradiol on fibronectin mRNA and protein
levels
The effect of E2 on FN expression was examined using
RT-PCR and western blot analysis. In untreated samples,
FN mRNA and protein levels in SSc patient fibroblasts
were higher than those in their healthy twins. E2 increased
FN mRNA and protein levels in healthy twin and SSc
fibroblasts (Figure 1A,B). E2 increased FN mRNA and
protein levels in a time-dependent and dose-dependent
manner in cell supernatants and ECM (Figure 1C,D).
E2 induced production of total FN and EDA-domain-
containing matrix FN (Figure 1C) and the increase in
secreted FN was significant (Figure 1E). The ER antagonist
ICI 182,780 blocked the effect of E2 on FN mRNA and
protein expression but did not affect transforming growth
factor beta-induced FN levels (Figure 1F).
Signaling pathways mediating the effects of 17b-estradiol
on fibronectin induction
To investigate the mechanism mediating E2 induction of
FN, we pretreated skin fibroblasts with vehicle, MEK inhi-
bitor, PI3K inhibitor, or p38 MAPK inhibitor for 1 hour
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prior to the addition of E2. FN protein levels were assessed
by western blot analysis 48 hours post treatment. PI3K
inhibitor and p38 MAPK inhibitor attenuated the
E2-mediated increase of FN (Figure 2A). MEK inhibitor
had a more modest effect on E2 induction of FN. We also
examined the effect of the chemical inhibitors on ERa and
ERb. ERa was increased by E2 and this increase was
blocked by PI3K inhibitor, p38 MAPK inhibitor, and MEK
inhibitor. There was no significant difference in the
expression of ERb under the same conditions (Figure 2A).
Effect of ER ligands on fibronectin expression
To assess the individual effects of ERa and/or ERb on FN
expression, we used PPT, an ERa ligand, and genistein, an
ERb ligand. Primary fibroblasts were treated with vehicle,
E2, PPT, or genistein for 48 hours. ECM was harvested
and analyzed by western blot. Vitronectin was detected as
an ECM loading control. E2 and PPT increased FN pro-
tein levels in the ECM (Figure 2B). Genistein modestly
increased FN protein levels (Figure 2B). Vitronectin levels
were not altered by any of the treatments.
Estradiol and ERa agonist induce increased dermal and
collagen bundle thickening and fibronectin deposition in
human skin
To further examine the effect of E2 in skin tissues, the
dermal and collagen bundle thicknesses in dermis were
assessed using an ex vivo organ culture system. Explanted
skin tissues on 35 mm well plates were treated with E2,
ERa or ERb agonists (PPT or genistein, respectively), or
vehicle (ethanol for E2 and PPT, and dimethylsulfoxide
for genistein) for 7 days, and skin sections were stained
with H & E. As shown in Figure 3, E2 and PPT induce
increase of dermal thickness (Figure 3A) and collagen
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Figure 1 Estradiol increases fibronectin production in vitro. (A) Fibronectin (FN) mRNA expression in primary skin fibroblasts from twins
discordant for systemic sclerosis (SSc). FN mRNA was analyzed after 24-hour treatment with 10 nM 17b-estradiol (E2), vehicle (V), or no
treatment (control, C) using RT-PCR. Assays were done in duplicate. (B) FN protein expression in culture supernatants of primary skin fibroblasts.
FN protein expression was analyzed by western blot in untreated, E2-treated or vehicle-treated fibroblasts for 48 hours. SSc, SSc patient; healthy,
healthy twin of an SSc patient; control, unrelated healthy donor. (C) FN protein expression in the extracellular matrix (ECM) and culture
supernatants (Sup) of normal skin fibroblasts treated with vehicle, transforming growth factor beta (TGFb), or E2. ECM and culture supernatants
were harvested at the indicated time points. (D) FN levels in the ECM and Sup of normal skin fibroblasts stimulated with vehicle and different
concentrations of E2 ranging from 0.1 to 10 nM. (E) Graphical summary of FN levels representing data from four independent experiments. *P =
0.0036. (F) Effect of E2 blockade on the expression of FN protein in the ECM and Sup of normal skin fibroblasts stimulated with E2. Cells were
treated with E2 for 48 hours in the presence or absence of the ER antagonist ICI 182,780.
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bundle thickness (Figure 3B) compared with vehicle (der-
mis: 1.61 ± 0.12, P <0.05 and 1.54 ± 0.05, P <0.05, respec-
tively; collagen bundles: 2.62 ± 0.18, P <0.05 and 1.84 ±
0.15, P <0.05, respectively), and ICI 182,780 blocked the
effect of E2. On the contrary, genistein did not induce
thickening of dermis or collagen bundles (Figure 4A,B).
We also assessed the extent of deposition of FN using
immunohistochemistry. As shown in Figure 4, the results
of FN deposition in collagen bundles were similar to
those for thickness of skin and collagen bundles. E2 thus
induces skin fibrosis, and this effect is mediated by ERa.
Circulating levels of 17b-estradiol and estrone are
significantly increased in postmenopausal patients with
systemic sclerosis
Patient and control E2 serum samples were divided into
low (<5 pg/ml), intermediate (5 to 10 pg/ml), and high
(>10 pg/ml) levels (Table 1). Similarly, patient and control
estrone serum samples were divided into low (<15 pg/ml),
intermediate (15 to 75 pg/ml), and high (>75 pg/ml) levels
(Table 1). There was a significant difference between SSc
patient and control E2 and estrone levels (P = 0.04 and
P = 0.006, respectively). The frequency of the data points
is shown in the dot plots of Figure 5. Levels of E2 and
estrone were also analyzed by disease specific clinical man-
ifestations occurring at any time during the illness.
Although the associations did not reach statistical signifi-
cance, a larger proportion of patients with high estrone
levels (42%) had gastrointestinal involvement compared
with those patients with low estrone levels (17%, P = 0.07).
Discussion
We present data establishing a role for E2 in the induction
of a fibrotic phenotype. E2 was previously demonstrated
to increase collagen during wound healing [16,17]. We
and others have previously reported that FN mRNA levels
in SSc dermal fibroblasts are up to 10-fold greater than
those in healthy donors [18,19]. E2 increases FN mRNA in
cardiac fibroblasts and this increase was associated with
ECM remodeling [20]. However, the mechanism(s) med-
iating the effect of E2 on FN expression are poorly under-
stood. To our knowledge, this report is the first to
delineate the mechanisms mediating E2 induction of FN
in human skin.
SSc is more frequent in women than men and the
female:male ratio further increases to 10:1 during the
child-bearing years [1,3]. E2 levels in women during the
child-bearing years are significantly higher than those in
postmenopausal women. The menstrual cycle has four
phases (menstrual, follicular, ovulatory, and luteal), and
each phase is characterized by different circulating levels
of E2 [21]. These E2 levels during ovulation are 490 to
1,710 pmol/l (mean 1,087 pmol/l) and exceed levels
detected during the other phases [22]. E2 levels in postme-
nopausal women are 2 to 18 pg/ml (mean 7.6 pg/ml) [23],
which is equivalent to 28 pmol/l and significantly lower
than levels in women of child-bearing age. Circulating E2
levels are thus increased in the age range during which the
SSc female:male ratio is highest. E2 levels that promoted a
fibrotic phenotype in our assays were physiological and
ranged from 0.1 to 10 nM. These levels were similar to
levels measured in the circulation of women during ovula-
tion (average 1 nM) [22].
Our data confirm the expression of ERa and ERb in pri-
mary dermal fibroblasts [24]. We further show that PPT,
an ERa specific ligand, increases FN production. Moreover,
ERa is increased by E2 treatment of skin fibroblasts. These
results suggest that ERa is the main regulator of E2-
mediated FN expression in dermal fibroblasts. Interestingly,
ERb levels were much lower in SSc patient fibroblasts than
in healthy twin fibroblasts (data not shown). ERb expres-
sion is decreased in colon and prostate cancers and its
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Figure 2 Estradiol promotes fibronectin production via specific signaling cascades. (A) Fibronectin (FN) protein levels in the cellular lysates
of normal skin fibroblasts. Normal skin fibroblasts were stimulated with 17b-estradiol (E2) for 48 hours in the presence or absence of the
following chemical inhibitors: MEK inhibitor (MEKi), phosphoinositol 3-kinase inhibitor (PI3Ki), and p38 kinase inhibitor (p38Ki). Cellular lysates
were analyzed by western blot using anti-EDA-FN, estrogen receptor (ER)a, ERb, and GAPDH antibodies. (B) Effect of E2 ligands on the
expression and deposition of FN in the extracellular matrix (ECM) of normal skin fibroblasts. PPT, propyl-pyrazole-triol. Primary fibroblasts were
cultured with vehicle (dimethylsulfoxide (DMSO), ethanol (EtOH)), E2, PPT, or genistein for 48 hours. ECM was analyzed by western blot using
anti-EDA-FN and anti-vitronectin antibodies. Ethanol was used as vehicle for E2 and PPT. DMSO was used as a vehicle for genistein.
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reduced expression is related to tumor cell dedifferentia-
tion [25-30]. Global antagonism of ERa transcriptional
activity by ERb has been reported [31]. ERb represses
several ERa-mediated effects, including fat reduction and
cellular proliferation in the uterus and prostate [31]. We
further show that E2, acting via ERa, exerts profibrotic
effects. The FN-promoting effects of E2 were confirmed in
vitro in dermal fibroblasts during the preparation of this
manuscript by Soldano and colleagues [32]. These effects
are probably tissue specific, however, since E2 attenuates
tubulointerstitial fibrosis in diabetic nephropathy [33]. In
summary, our findings suggest that ERb could play a pro-
tective role in SSc. A similar antifibrotic role for ERb was
recently reported in a model of cardiac fibrosis [34].
Further studies are needed to determine whether ERa and
ERb can exert converter-regulatory effects in the modu-
lation of FN expression in SSc and normal dermal
fibroblasts.
ER acts as a ligand-activated transcription factor. The
classical mechanism of ER action involves estrogen bind-
ing to nuclear receptors followed by receptor dimerization
and binding to specific response elements known as estro-
gen response elements located in the promoters of target
genes. Dimerized receptors can also bind other transcrip-
tion factors such as AP-1 and SP-1 [35-37]. Estrogens
exert some of their effects through the action of ERs on
gene expression, but a number of other effects of estro-
gens are so rapid that they cannot rely on the activation of
RNA or protein synthesis. These actions are known as
nongenomic actions and are believed to be mediated
through membrane-associated ERs. Most endogenous
plasma membrane ERs exist as homodimers in the pre-
sence of E2 [38] and mediate rapid E2 activation of a num-
ber of signaling cascades, including cyclic AMP, PI3K,
phospholipase C, and MAPK [39]. These signaling path-
ways regulate cytokine production, apoptosis, cell cycle
arrest, regulation of RNA splicing or stabilization, and
tumor cell differentiation [40,41].
The MAPK superfamily consists of three well-character-
ized subfamilies [42]. Extracellular signal-regulated kinases
respond to growth factors or other external mitogenic sig-
nals and are involved in promoting cell proliferation. The
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Figure 3 Estradiol promotes the development of fibrosis ex vivo in human skin. (A) Estrogen and estrogen receptor (ERa) agonist induce
skin thickening ex vivo. Human skin samples were plated on six-well plates and treated with ethanol (EtOH), 17b-estradiol (E2), estradiol with ICI
182,780 (E2+ICI), propyl-pyrazole-triol (PPT), dimethylsulfoxide (DMSO), and genistein for 7 days. (A) Images of H & E-stained sections taken at
40× magnification. Skin thickness was measured and the ratio of the thickness compared with vehicle control (EtOH or DMSO) was calculated as
an arbitrary unit. Data shown are from three independent experiments. *P >0.05 by Mann-Whitney U test. (B) Estrogen and ERa agonist also
induce collagen bundle thickening in ex vivo. Human skin samples were treated with EtOH, E2, E2+ICI, PPT, DMSO, or genistein for 7 days.
Images of H & E-stained sections are shown. Images taken at 800× magnification. Thickness of collagen bundles was measured and the ratio
compared with vehicle control (EtOH or DMSO) was calculated as an arbitrary unit. Data shown are from three independent experiments. *P
>0.05 by Mann-Whitney U test.
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p38 MAPK and c-Jun N-terminal kinase pathways are dis-
tinguished by generally being activated in response to
stress and are thus called the stress-activated kinases that
promote inflammation and programmed cell death [43].
PI3K also has an important role in mitosis, apoptosis,
motility, proliferation, and differentiation [44]. We have
demonstrated that all three kinases (extracellular signal-
regulated kinase MAPK, p38K MAPK and PI3K) regulate
E2 signaling and its induction of FN expression, with FN
induction being mainly regulated by PI3K and p38 MAPK
and to a lesser extent by extracellular signal-regulated
kinase MAPK. PI3K and p38 MAPKs have also been
reported to regulate E2/ER’s anti-apoptotic action on car-
diomyocytes [41]. Our findings support the role of these
E2 signaling cascades in skin fibroblasts and in the regula-
tion of ECM production.
We had previously shown that human skin maintained
in an organ culture system can be used to recapitulate in
vivo events and to test the efficacy of antifibrotic agents
[13]. Our current data demonstrate that E2 can exert
profibrotic activity ex vivo in human skin and that this
effect can be specifically blocked by ICI 182,780. The
extension of our data describing the profibrotic effects of
E2 to human tissues supports the applicability of our
findings to human disease and the potential therapeutic
effects of ICI 182,780 for human fibrosis.
The preponderance of SSc in women suggests that
estrogens play a role in disease pathogenesis. We show
that circulating E2 and estrone levels are elevated in post-
menopausal patients with diffuse cutaneous SSc com-
pared with healthy women, implicating estrogens, and
specifically E2 and estrone, in the disease process.
Numerous studies have shown that dermal skin thickness
and collagen content increase in women on estrogen
replacement therapy [45,46]. Furthermore, clinical trials
have shown that postmenopausal women on HRT have
thicker skin compared with women not taking HRT
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Figure 4 Estradiol induces fibronectin production ex vivo in human skin. Estrogen and estrogen receptor alpha (ERa) agonist induce
fibronectin expression ex vivo. Human skin samples were plated on six-well plates and treated with ethanol (EtOH), 17b-estradiol (E2), estradiol
with ICI 182,780 (E2+ICI), propyl-pyrazole-triol (PPT), dimethylsulfoxide (DMSO), and genistein and incubated for 7 days. Immunohistochemistry
was performed using anti-fibronectin antibody and visualized with aminoethyl carbazole (red).
Table 1 Levels of estradiol and estrone in patients with
diffuse cutaneous systemic sclerosis and healthy controls
Low Intermediate High Total
Estradiola
Controls 14 20 1 35
dcSSc 34 24 10 68
Total 48 44 11 103
Estroneb
Controls 7 18 0 25
dcSSc 9 31 15 55
Total 16 49 15 80
aLow (<5 pg/ml), intermediate (5 to 10 pg/ml), and high (>10 pg/ml); P = 0.04
for controls versus diffuse cutaneous systemic sclerosis (dcSSc) using chi-
square/Fisher’s exact test. bLow (<15 pg/ml), intermediate (15 to 75 pg/ml),
and high (>75 pg/ml); P = 0.006 for controls versus dcSSc using chi-square/
Fisher’s exact test.
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[47-50]. The profibrotic role of E2 has been confirmed in
the bleomycin-induced rat lung fibrosis model where
female animals had a more profound fibrotic response
compared with males, which was attenuated following
ovariectomy and accentuated with HRT [51]. In mice,
castration decreases skin thickness and ovariectomy
reduces expression of matrix-associated proteoglycans
[52], suggesting that the absence of sex steroid hormones
reduces expression of ECM components. These reports
further support the role of estrogens in the development
of fibrosis in SSc and suggest that E2 can be a trigger of
ECM production and fibrosis.
Estrogen has been implicated in autoimmune diseases
based on its ability to promote B-lymphocyte survival and
activation, thus facilitating autoreactivity [53]. In the set-
ting of inflammation, accelerated conversion of androgens
to estrogen metabolites via aromatase occurs in the per-
ipheral tissues [53]. This peripheral conversion may con-
tribute to increased E2 levels in postmenopausal patients
with SSc. Concentrations of E2 in skin from individuals
with SSc probably exceed those detected in the circulation
due to local hormone production mediated by aromatase
[53]. Our ex vivo human skin model mimics the effect of
peripheral estrogens found in postmenopausal women
with SSc. In autoimmunity, conversion is accelerated by
the induction of aromatase activity by inflammatory cyto-
kines such as IL-6, which is increased in autoimmune
diseases including SSc [54,55].
Conclusion
We have identified E2 as an inducer of FN expression in
skin fibroblasts obtained from SSc patients and healthy
donors. The effects of E2 on FN were mainly regulated
via ERa and the E2/ER downstream signaling cascades,
PI3K and p38 MAPK. We also demonstrated that E2 is
fibrotic ex vivo and that ICI 182,780 can be used effec-
tively to inhibit dermal fibrosis. The profibrotic effect of
E2 and the increased circulating levels of E2 and estrone
may explain, at least in part, the higher frequency of SSc
in women.
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